Chemocentryx Quick Ratio (CCXI) starting from the second quarter 2026 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Chemocentryx Inc.  (NASDAQ: CCXI)

Chemocentryx's Quick Ratio

CCXI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.01 a new company low.

Within Major Pharmaceutical Preparations industry 656 other companies have achieved higher Quick Ratio than Chemocentryx in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1040 to 6221.

Explain Quick Ratio?
How much Cash & cash equivalents CCXI´s has?
What are CCXI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CCXI Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q2		 (Jun 30 2022)
Q1		 (Mar 31 2022)
Q4
Y / Y Current Liabilities Change 103.28 % -99.87 % -99.91 % 37.38 % 25.72 %
Y / Y Cash & cash equivalent Change -99.63 % -99.84 % -99.73 % 5.12 % -9.48 %
Quick Ratio MRQ 0.01 5.09 13.22 4.32 4.95
CCXI's Total Ranking # 6221 # 1040 # # #
Seq. Current Liabilities Change 173432.95 % 44.7 % -99.93 % 10.57 % 9.19 %
Seq. Cash & cash equivalent Change 205.42 % -44.3 % -99.78 % -3.52 % 28.78 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 657
Healthcare Sector # 1310
Overall Market # 6221


Quick Ratio Statistics
High Average Low
26.59 8.12 0.01
(Dec 31 2015)   (Jun 30 2026)




Financial Statements
Chemocentryx's Current Liabilities $ 140 Millions Visit CCXI's Balance sheet
Chemocentryx's Cash & cash equivalent $ 1 Millions Visit CCXI's Balance sheet
Source of CCXI's Sales Visit CCXI's Sales by Geography


Cumulative Chemocentryx's Quick Ratio

CCXI's Quick Ratio for the trailling 12 Months

CCXI Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -12.6 % -37.8 % -17.53 % 12.11 % 3.02 %
Y / Y Cash & cash equivalent TTM Growth -72.12 % -45.18 % -49.6 % -41.49 % -47.2 %
Quick Ratio TTM 1.53 4.62 4.49 4.49 4.8
Total Ranking TTM # 5364 # 5448 # # #
Seq. Current Liabilities TTM Growth 49 % -30.26 % -22.38 % 8.37 % 6.04 %
Seq. Cash & cash equivalent TTM Growth -50.62 % -28.26 % -22.33 % 1.35 % -2.92 %

Quick ratio ranking by company, industry and sector >> Back to CCXI Financial Strength Comparisons >> Go to Compare CCXI Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $139.87 millions, cumulative Quick Ratio decreased to 1.53 above the CCXI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 590 other companies have achieved higher Quick Ratio than Chemocentryx. While Quick Ratio overall ranking has improved so far to 5364, from total ranking during the twelve months ending first quarter 2026 at 5448.

Explain Quick Ratio?
How much Cash & cash equivalents CCXI´s has?
What are CCXI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 591
Healthcare Sector # 1184
Within the Market # 5364


trailing twelve months Quick Ratio Statistics
High Average Low
3.24 1.45 0.41
(Mar 31 2014)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Northwest Biotherapeutics Inc  0.01 $ 0.595  Millions$ 42.982  Millions
Oncotelic Therapeutics Inc   0.01 $ 0.186  Millions$ 17.907  Millions
Os Therapies Incorporated  0.01 $ 0.205  Millions$ 20.653  Millions
The Greater Cannabis Company Inc   0.01 $ 0.000  Millions$ 0.012  Millions
Chemocentryx Inc.  0.01 $ 1.253  Millions$ 139.868  Millions
NIKA PHARMACEUTICALS, INC  0.01 $ 0.003  Millions$ 0.341  Millions
Evofem Biosciences Inc   0.01 $ 0.714  Millions$ 88.615  Millions
Rain Enhancement Technologies Holdco Inc   0.01 $ 0.071  Millions$ 13.574  Millions
IMPACT BIOMEDICAL INC. 0.00 $ 0.010  Millions$ 2.045  Millions
Semnur Pharmaceuticals Inc 0.00 $ 0.039  Millions$ 10.672  Millions
Cnbx Pharmaceuticals Inc 0.00 $ 0.010  Millions$ 2.673  Millions
Accustem Sciences Inc 0.00 $ 0.013  Millions$ 5.724  Millions

Date modified: 2026-09-26T07:44:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.